Skip to main contentAI and Advanced
/
KREBSBIO · NSEMarket ticker unavailable · configure an authorised index feed
KR
NSE · Equity shares · Biotechnology & Drugs0.06 · 0.11%
Krebs Biochemicals & Industries Ltd KREBSBIO
NSE:INR 56.36
BSE:INR 54.44
Data quality and coveragePrice, company fundamentals and optional research feeds are tracked separately.
Headline priceLast market snapshot
Company fundamentalsStale · last-known data
Research sections8 of 9 availableMissing source values remain unavailable, never zero-filled.
Temporary source issue: live-price. Available sections remain usable while the affected layer retries on a later request.
AI analysis and Advanced tools for KREBSBIO
Analysis, reports, chat and Advanced access use the same Rusaka Markets account. The backend remains authoritative for roles, subscriptions, credits and permissions.
Snapshot
Price and key statistics
Reported and computed values remain separate; missing values are not converted to zero.
Previous closeINR 56.3
Day rangeINR 54.66 — INR 57.8
52-week rangeINR 38.33 — INR 82.49
Volume5,062
Market cap117.35
P/ENot available
Fundamental highlightsReported values unless marked as computed
Revenue (INR Cr)23.73
Net Income (INR Cr)-16.93
EPS-7.85
Research path: Interpret Krebs Biochemicals & Industries Ltd's snapshot alongside the wider market dashboard, the financial-statement research guide and the valuation-ratios field guide.
Validated OHLC
Interactive price chart
Crosshair, OHLCV tooltip, indicators, volume, zoom and pan use the same candle API as the advanced workspace.
KREBSBIOKrebs Biochemicals & Industries Ltd1d · INR · NSE
Loading validated candles…
Auditable calculations
Daily technical summary
Calculated from validated daily candles. Descriptive research only.
Calculating technicals…
Indicators describe price behaviour and volatility; they are not a BUY, NEUTRAL or SELL recommendation.
Company reporting
Financial statements
IND AS · INR crore
| Metric | 2026 | 2025 | 2024 |
|---|---|---|---|
| Total Liabilities Shareholders' Equity | 163.25 | 169.04 | 178.17 |
| Cash Equivalents | 0.13 | Not available | Not available |
| Other Liabilities Total | 49.39 | 50.5 | 52.06 |
| Long Term Debt | 163.55 | 161.25 | 183.5 |
| Common Stock Total | 21.56 | 21.56 | 21.56 |
| Other Current Assets Total | 3.6 | 0.12 | 0.07 |
| Total Assets | 163.25 | 169.04 | 178.17 |
| Total Equity | -162.75 | -146.24 | -119.22 |
| Long Term Investments | 2.71 | Not available | Not available |
| Retained Earnings(Accumulated Deficit) | -184.32 | -297.26 | -270.24 |
| Total Common Shares Outstanding | 2.16 | 2.16 | 2.16 |
| Tangible Book Valueper Share Common Eq | -75.62 | -68.9 | -56.46 |
| Total Liabilities | 326 | 315.27 | 297.39 |
| Total Debt | 224.84 | 212.21 | 193.68 |
| Short Term Investments | 0.18 | Not available | Not available |
| Cashand Short Term Investments | 0.31 | 0.02 | 0.07 |
| Total Receivables Net | 0 | 3.05 | 6.68 |
| Notes Payable/Short Term Debt | 61.29 | 50.96 | 9.93 |
| Accounts Receivable-Trade Net | 0 | 0.22 | 4.89 |
| Property/Plant/Equipment Total-Net | 143.01 | 146.47 | 149.46 |
| Total Current Liabilities | 113.07 | 103.53 | 61.83 |
| Total Inventory | 5.7 | 6.6 | 10.24 |
| Accounts Payable | 13.76 | 18.15 | 18.97 |
| Other Currentliabilities Total | 38.02 | 19.42 | 21.65 |
| Total Long Term Debt | 163.55 | 161.25 | 183.5 |
| Intangibles Net | 0.29 | 2.32 | 2.5 |
| Other Long Term Assets Total | 7.62 | 2.82 | 2.5 |
| Total Current Assets | 9.62 | 10.26 | 17.44 |
| Accumulated Depreciation Total | Not available | -166.05 | -160.34 |
| Accrued Expenses | Not available | 15 | 11.04 |
| Other Equity Total | Not available | 11.44 | 11.44 |
| Prepaid Expenses | Not available | 0.47 | 0.38 |
| Current Portof LT Debt/Capital Leases | Not available | 0 | 0.25 |
| Additional Paid-In Capital | Not available | 118.02 | 118.02 |
| Cash | Not available | 0.02 | 0.07 |
| Property/Plant/Equipment Total-Gross | Not available | 311.29 | 309.64 |
| Note Receivable-Long Term | Not available | 7.17 | 6.27 |
Fundamentals
Valuation and ratios
Valuation
Price to Sale Ratio4.95
Risk and consensus
Source-qualified signals
Risk metrics
Overall RiskHigh risk
Board Risk62.92
Analyst consensus
Analyst consensus unavailable.
Provider consensus uses a 1 (Strong Buy) to 5 (Strong Sell) score. The payload does not include price targets, so none are inferred from 52-week prices or recommendation percentages.Industry context
Peer comparison
Only peers present in the company profile payload are displayed.
Peer data unavailable in the company profile payload.
Shareholding
Ownership
- Promoter
- 72.74%
- FII
- 0.49%
- Other
- 26.77%
Company intelligence
Latest relevant news
Source, timestamp and external destination are shown. Provider relevance scores are not available.
Krebs Biochemicals & Industries Ltd Reports Flat Quarterly Performance Amid Prolonged Downtrend - Markets MojoMarket news · 3 Jun 2026, 2:58 am
Krebs Biochemicals & Industries Ltd Reports Flat Quarterly Performance Amid Prolonged Downtrend Markets Mojo
Krebs Biochemicals & Industries Ltd is Rated Strong Sell - Markets MojoMarket news · 2 Jun 2026, 4:01 pm
Krebs Biochemicals & Industries Ltd is Rated Strong Sell Markets Mojo
Krebs Biochemicals & Industries Ltd Locks at Upper Circuit With 4.78% Gain — Buyers Queue, Sellers Absent - Markets MojoMarket news · 27 May 2026, 10:20 am
Krebs Biochemicals & Industries Ltd Locks at Upper Circuit With 4.78% Gain — Buyers Queue, Sellers Absent Markets Mojo
Krebs Biochemicals & Industries Ltd Locks at Upper Circuit With 5% Gain — Buyers Queue, Sellers Absent - Markets MojoMarket news · 26 May 2026, 1:09 pm
Krebs Biochemicals & Industries Ltd Locks at Upper Circuit With 5% Gain — Buyers Queue, Sellers Absent Markets Mojo
A 5% Single-Day Surge Takes Krebs Biochemicals & Industries Ltd to Its Upper Circuit Limit of Rs 61.81 - Markets MojoMarket news · 25 May 2026, 1:48 pm
A 5% Single-Day Surge Takes Krebs Biochemicals & Industries Ltd to Its Upper Circuit Limit of Rs 61.81 Markets Mojo
Krebs Biochemicals FY26 Loss Narrows to ₹1,693.31 lacs - scanx.tradeMarket news · 23 May 2026, 12:30 pm
Krebs Biochemicals FY26 Loss Narrows to ₹1,693.31 lacs scanx.trade
Corporate actions
Events
- board MeetingsAudited Results
- board MeetingsTo Consider Other business matters.
- board MeetingsQuarterly Results
- annual General MeetingAGM
- board MeetingsTo Consider Other business matters.
- board MeetingsAudited Results
- annual General MeetingPOM
- board MeetingsTo Consider Other business matters.
Rusaka Markets Community
Discussion and sentiment for Krebs Biochemicals & Industries Ltd
Posts are linked to the canonical company record. Community BUY, NEUTRAL and SELL opinions are user-generated, moderated and separate from analyst consensus and Rusaka Markets AI.
Checking your Rusaka Markets account…
Company profile
Business information
What the company does
Not available
Company facts
- Industry
- Biotechnology & Drugs
- Sector
- Biotechnology & Drugs
- NSE Code
- KREBSBIO
- BSE Code
- 524518
Questions
Stock FAQ
What is the symbol and ISIN of Krebs Biochemicals & Industries Ltd?
Krebs Biochemicals & Industries Ltd has the symbol KREBSBIO and ISIN - INE268B01013.
What is the current price of Krebs Biochemicals & Industries Ltd?
Krebs Biochemicals & Industries Ltd is currently trading at INR 56.36.
What are the year high and year low of Krebs Biochemicals & Industries Ltd?
Krebs Biochemicals & Industries Ltd has a year high of INR 82.49 and a year low of INR 38.33.
What is the market capitalization of Krebs Biochemicals & Industries Ltd?
Krebs Biochemicals & Industries Ltd has a market capitalization of INR 117.35 crore.
What is the P/E ratio of Krebs Biochemicals & Industries Ltd?
Krebs Biochemicals & Industries Ltd has a P/E ratio of NA.
What is the dividend yield of Krebs Biochemicals & Industries Ltd?
Krebs Biochemicals & Industries Ltd has a dividend yield of NA.
How is the financial performance of Krebs Biochemicals & Industries Ltd based on revenue, net income, and EPS?
Krebs Biochemicals & Industries Ltd has revenue of INR 23.73 crore, net income of INR -16.93 crore, and EPS of NA.
What is the book value of Krebs Biochemicals & Industries Ltd?
Krebs Biochemicals & Industries Ltd has a book value of NA.
What is the debt-to-equity ratio of Krebs Biochemicals & Industries Ltd?
Krebs Biochemicals & Industries Ltd has a debt-to-equity ratio of NA.
What are the price-to-book and price-to-sales ratios of Krebs Biochemicals & Industries Ltd?
Krebs Biochemicals & Industries Ltd has a price-to-book ratio of NA and a price-to-sales ratio of 4.95.
Corporate-action adjustment is provider-defined. Rusaka Markets research and computed indicators are not investment advice.